Gossamer Bio Faces Class Action Lawsuit After Phase 3 Trial Failure and Significant Stock Drop

Gossamer Bio, Inc. Hit by Class Action Following Phase 3 Trial Disappointment

Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a significant securities class action lawsuit after announcing disappointing results from its Phase 3 PROSERA study. The lawsuit, initiated by Hagens Berman, aims to represent investors who purchased or acquired Gossamer securities from June 16, 2025, to February 20, 2026. The major announcement came on February 23, 2026, when the company revealed that the study did not meet its primary endpoint, causing a dramatic 80% drop in stock value.

The PROSERA trial evaluated the efficacy of seralutinib for treating pulmonary arterial hypertension (PAH), and investor expectations were high. Prior to the announcement, Gossamer had touted seralutinib as a groundbreaking potential treatment, even referencing successful Phase 3 trial outcomes from competitors like Merck. However, when the trial results were released, they failed to show the expected improvements in patient health metrics that investors had anticipated.

Hagens Berman's lawsuit claims that Gossamer misled investors about the robustness of the Phase 3 trial design, including details about patient recruitment and monitoring protocols. Specifically, it is alleged that management was aware of potential issues within the study but chose to portray confidence to the market regarding the trial's success.

On the day the negative results were announced, it was revealed that the placebo effect among participants was significantly influencing the study outcomes, particularly in the Latin American cohort where many previously treated patients showed unexpectedly positive results on placebo. Gossamer management noted that these conditions diluted the overall treatment effect, leading to statistically insignificant efficacy in comparison to placebo groups.

This stock drop has led to an investigation by Hagens Berman into whether Gossamer's disclosures leading up to the trial were appropriate, as investors seek to understand the full extent of the company's claims versus actual outcomes. The firm is urging those who have suffered financial losses related to Gossamer investments during the class period to come forward. Individuals with substantial non-public knowledge are particularly valuable for the ongoing investigation, and the firm is keen on gathering more information from any whistleblowers willing to assist.

As it stands, Gossamer's stock issues have intensified, especially after the company revealed on April 9, 2026, that it had not met the Nasdaq's minimum share price requirement, further complicating its financial standing post-trial.

In essence, Gossamer Bio is now at a crossroads, navigating legal troubles as it faces the fallout from its clinical trial setbacks. Investors, meanwhile, are left grappling with the implications of this class action lawsuit and the potential recovery of their investments, which were promised exceptional returns only to be rendered nearly worthless overnight.

The case is ongoing, and those interested in participating or learning more about their rights as investors can visit Hagens Berman's website for additional resources. The deadline for lead plaintiff applications is June 1, 2026. Investors are strongly encouraged to take action quickly as these legal complexities unfold.

For further updates on this case, follow Hagens Berman on their social media channels or reach out directly via their contact points to stay informed about the progress and any potential developments. As the situation continues to evolve, Gossamer Bio's future remains uncertain, making it a critical point of watch for industry analysts and investors alike.